ASCO 2026 | KEYNOTE-942: 5 year update of intismeran and pembrolizumab in melanoma
Matteo Carlino, FRACP, PhD, The University of Sydney and Westmead Hospital, Sydney, Australia, presents 5-year follow-up results from KEYNOTE-942 (NCT03897881), a Phase IIb study evaluating intismeran autogene (intismeran), an mRNA-based individualized neoantigen therapy, plus pembrolizumab versus pembrolizumab alone in resected high-risk melanoma. Results demonstrated sustained and durable reductions in recurrence-free and distant metastasis-free survival risk with the combination. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Keynote 942 is a randomized phase 2 patient study in patients with resected high-risk melanoma. The standard treatment for such patients is adjuvant therapy with a drug such as pembrolizumab, and the trial randomized patients to a combination of intismeran, which is a personalized neoantigen therapy, plus pembrolizumab versus pembrolizumab alone. What we hoped would happen and what the results, I think, show is that the intismeran leads to an anti-tumor T-cell response against those neoantigens, leading to a reduction in the risk of relapse and an improvement in the distant metastasis-free survival...
Keynote 942 is a randomized phase 2 patient study in patients with resected high-risk melanoma. The standard treatment for such patients is adjuvant therapy with a drug such as pembrolizumab, and the trial randomized patients to a combination of intismeran, which is a personalized neoantigen therapy, plus pembrolizumab versus pembrolizumab alone. What we hoped would happen and what the results, I think, show is that the intismeran leads to an anti-tumor T-cell response against those neoantigens, leading to a reduction in the risk of relapse and an improvement in the distant metastasis-free survival.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
